A trump card for challengers

As we bear witness to the rising popularity of the new post-grant proceedings in the US, we can reflect upon the long-standing procedures for pre-grant observations and post-grant oppositions at the European Patent Office (EPO).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

More features

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

Built to be bought? What makes companies acquisition-ready

Patent lawyers and judges discuss lofty UPC issues in grand London venue

Abbott clinches 18-country PI in glucose monitoring feud

UK firm hires head of IP with commercial and technical nous

G 1/25: EPO settles controversial patent description question

A trump card for challengers

More on this story

Editor's picks

Editor's picks

More features